View clinical trials related to Neoplasm, Residual.
Filter by:The purpose of this study is to determine if WT1 is an adequate measurement of minimal residual disease in leukemic patients.
Metastatic bone disease is an important prognostic factor for survival which will in median be close to two years after first diagnosis of osseous metastases. This open-label study will investigate the safety and efficacy of zoledronic acid in patients with breast cancer and minimal residual disease in the bone marrow.